23 research outputs found
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for old or unfit patients remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811) prospective, multicenter, phase 2 trial, we tested the efficacy and safety of ponatinib plus prednisone in newly diagnosed patients with Ph+ ALL 6560 years, or unfit for intensive chemotherapy and stem cell transplantation. Forty-four patients received oral ponatinib 45 mg/d for 48 weeks (core phase), with prednisone tapered to 60 mg/m2/d from days-14-29. Prophylactic intrathecal chemotherapy was administered monthly. Median age was 66.5 years (range, 26-85). The primary endpoint (complete hematologic response [CHR] at 24 weeks) was reached in 38/44 patients (86.4%); complete molecular response (CMR) in 18/44 patients (40.9%) at 24 weeks. 61.4% of patients completed the core phase. As of 24 April 2020, median event-free survival was 14.31 months (95% CI 9.30-22.31). Median overall survival and duration of CHR were not reached; median duration of CMR was 11.6 months. Most common treatment-emergent adverse events (TEAEs) were rash (36.4%), asthenia (22.7%), alanine transaminase increase (15.9%), erythema (15.9%), and \u3b3-glutamyltransferase increase (15.9%). Cardiac and vascular TEAEs occurred in 29.5% (grade 653, 18.2%) and 27.3% (grade 653, 15.9%), respectively. Dose reductions, interruptions, and discontinuations due to TEAEs occurred in 43.2%, 43.2%, and 27.3% of patients, respectively; 5 patients had fatal TEAEs. Ponatinib and prednisone showed efficacy in unfit patients with Ph+ ALL; however, a lower ponatinib dose may be more appropriate in this population. This trial was registered at www.clinicaltrials.gov as #NCT01641107
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA; Italian Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed a project aimed at selecting the treatment policies that may increase the probability of TFR, taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the characteristics of leukemia, and the patient. A Delphi-like method was used to reach a consensus among the representatives of 50 centers of the CML WP. A consensus was reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the definition of the most appropriate age boundaries for the choice of first-line treatment, on the choice of the TKI for first-line treatment, and on the definition of the responses that do not require a change of the TKI (BCR-ABL1 6410% at 3 months, 641% at 6 months, 640.1% at 12 months, 640.01% at 24 months), and of the responses that require a change of the TKI, when the goal is TFR (BCR-ABL1 >10% at 3 and 6 months, >1% at 12 months, and >0.1% at 24 months). These suggestions may help optimize the treatment strategy for TFR
Recommended from our members
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia.
Approximately 18% of acute myeloid leukemia (AML) cases express a fusion transcript. However, few fusions are recurrent across AML and the identification of these rare chimeras is of interest to characterize AML patients. Here, we studied the transcriptome of 8 adult AML patients with poorly described chromosomal translocation(s), with the aim of identifying novel and rare fusion transcripts. We integrated RNA-sequencing data with multiple approaches including computational analysis, Sanger sequencing, fluorescence in situ hybridization and in vitro studies to assess the oncogenic potential of the ZEB2-BCL11B chimera. We detected 7 different fusions with partner genes involving transcription factors (OAZ-MAFK, ZEB2-BCL11B), tumor suppressors (SAV1-GYPB, PUF60-TYW1, CNOT2-WT1) and rearrangements associated with the loss of NF1 (CPD-PXT1, UTP6-CRLF3). Notably, ZEB2-BCL11B rearrangements co-occurred with FLT3 mutations and were associated with a poorly differentiated or mixed phenotype leukemia. Although the fusion alone did not transform murine c-Kit+ bone marrow cells, 45.4% of 14q32 non-rearranged AML cases were also BCL11B-positive, suggesting a more general and complex mechanism of leukemogenesis associated with BCL11B expression. Overall, by combining different approaches, we described rare fusion events contributing to the complexity of AML and we linked the expression of some chimeras to genomic alterations hitting known genes in AML
DXA-assessed changes in body composition in obese women following two different weight loss programs
DXA-assessed changes in body composition in obese women following two different weight loss programs
Objective: Changes in body composition during weight loss programs might have a significant
effect on long-term results. The aim of this study was to test these changes by dual energy x-ray
absorptiometry (DXA) in obese women enrolled into two different weight loss medical programs.
Methods: We prospectively studied 71 women assigned to either an intensive 3-mo cognitivebehavioral
therapy (CBT) or a 1-mo nutritional counseling plan (NCP). All patients underwent
DXA whole-body scan before treatment and after 3, 6, and 12 mo. Fat mass (FM), non-bone lean
mass (LM) and bone mineral content were assessed at whole-body and regional levels. Android
visceral adipose tissue (VAT) also was estimated.
Results: Twenty-three patients missed one or more follow-up controls and were excluded from the
final analysis. Twenty-seven patients (body mass index [BMI] 41.9 6.7 kg/m2) remained in the
CBT group and 21 (BMI 33.4 +/- 4 kg/m2) in the NCP group. The progressive decrease of BMI in both
groups was associated with reduced whole-body and regional FM, which was more marked in CBT.
During follow-up, a progressive decrease of total FM-to-LM and android FM-to-LM ratios were
observed both in CBT (D12-mo versus baseline -7.8 +/-9.6% and -9.5 +/-12.7%, respectively;
P < 0.01) and NCP (D12-mo versus baseline -5.9 +/-9.6% and -7 +/-13.4%, respectively; P < 0.05).
VAT was the parameter showing the largest decrease (-14.2 +/-17.4% and -11.3 +/-18.2% at 12 mo,
respectively in CBT and NCP; P < 0.05).
Conclusions: Lifestyle-induced weight loss is associated with selective changes in body composition
parameters, regardless of initial BMI and treatment program, limiting sarcopenic obesity. DXA may
quantify the metabolically healthier redistribution of total and regional FM and VAT
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas
Unfortunately, in the original online publication, the surname of the co-author “Mario Masarone” was incorrectly published. The co-author name is corrected here in this erratum